A recent study examined the efficacy of infliximab as a treatment for moderate to severe ulcerative colitis, according to a Medscape report.
The study included 134 ulcerative colitis patients. Of the subjects studied, 28 percent had acute severe ulcerative colitis, 38 percent had steroid-dependency and 33 percent had steroid-refractoriness.
● Rate of clinical response at week eight: 87 percent
● Rate of clinical remission at week eight: 45 percent
● Long-term clinical response: 71 percent
● Long-term clinical remission: 52 percent
● Adverse events affected 15 percent of patients
● Mucosal healing was the sole factor influencing long-term response.
More Articles on Gastroenterology:
9 Things Gastroenterologists Need to Know About the Gut Microbiome
5 Recent GI-Driven Center Openings & Plans
Does Patient Satisfaction Affect Colorectal Caner Treatment Outcomes?
The study included 134 ulcerative colitis patients. Of the subjects studied, 28 percent had acute severe ulcerative colitis, 38 percent had steroid-dependency and 33 percent had steroid-refractoriness.
● Rate of clinical response at week eight: 87 percent
● Rate of clinical remission at week eight: 45 percent
● Long-term clinical response: 71 percent
● Long-term clinical remission: 52 percent
● Adverse events affected 15 percent of patients
● Mucosal healing was the sole factor influencing long-term response.
More Articles on Gastroenterology:
9 Things Gastroenterologists Need to Know About the Gut Microbiome
5 Recent GI-Driven Center Openings & Plans
Does Patient Satisfaction Affect Colorectal Caner Treatment Outcomes?